huPBMC-NOG

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • huPBMC-NOG-F
    sp/sp;ko/ko
    NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac
  • huPBMC-NOG-M
    sp/sp;ko/y
    NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac
  • huPBMC-NOG is a model for investigation of adult/mature cell populations.
  • This model permits the assessment of effector and memory T cells.
  • PBMC engrafted mice are optimally suited for studies immediately following engraftment as Graft vs. Host Disease (GvHD) limiting survival time to 4-6 weeks. In addition, the GvHD response can be used as a screening system for T cell modulating drugs, with readouts including body weight and clinical condition, liver injury and immune cell infiltration into organs.
  • See Søndergaard et al. and Cox et al. for description of the GvHD model and its use in drug target validation.
  • Inquire about options such as irradiation, PBMCs of specific donor HLA types or patient-derived PBMCs.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Availability:

huPBMC-NOG mice are produced upon order and delivered within one week of injections.

Color:

Albino

Species:

Mouse


Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

Does your research require the use of neonates? Please contact us for more information on neonate access options.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758
Base pricing is $400 / €320 per mouse. The typical lead time for a cohort of standard huPBMC-NOG is three weeks. Please inquire for more details or to place your order.
huPBMC-NOG mouse chart #1
Chart #1: Human CD45+ cells were enumerated by flow cytometry at daily intervals follow PBMC engraftment. Significant engraftment was observed after 14 days. The majority of human CD45+ cells are CD3+ T cells.


huPBMC-NOG mouse chart #2
Chart #2: Irradiation exacerbates GvHD in PBMC engrafted NOG mice. Survival curves for PBMC engrafted NOG mice at increasing doses of radiation with, or without pre-treatment with anti-TNFa blocking antibody.